NCT04267081View on ClinicalTrials.gov

Study of Venetoclax in Combination With Azacytidine in AML Patients Selected Using Ex Vivo Drug Sensitivity Screening

PHASE2CompletedINTERVENTIONAL

Enrollment

104

Participants

Timeline

Start Date

February 12, 2020

Primary Completion Date

February 28, 2024

Study Completion Date

February 28, 2024

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

Venetoclax

Ex vivo venetoclax sensitivity testing is used for patient selection.

Trial Locations (1)

00029

HelsinkiUCH, Helsinki

All Listed Sponsors

lead

Helsinki University Central Hospital

OTHER

NCT04267081 - Study of Venetoclax in Combination With Azacytidine in AML Patients Selected Using Ex Vivo Drug Sensitivity Screening | Biotech Hunter | Biotech Hunter